Current Microsatellite Stability Results in Colon Cancer
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorTurkish Society of Colon and Rectal Surgery
About this trial
The goal of this prospective observational study is to learn more about how a specific type of DNA repair issue-called mismatch repair deficiency (dMMR)-affects colon cancer in people living in Turkey. The study will look at how often dMMR occurs, how it is reported, and how it relates to treatment outcomes.
The main questions it aims to answer are:
* How common is dMMR in colon cancer, and does it vary by where the tumor is in the colon? * How often is MSI (microsatellite instability) status reported in colon cancer biopsy reports before surgery? * How do different types of dMMR (such as MLH1/PMS2 loss, MSH2/MSH6 loss, or sporadic cases) affect survival over three years?
Participants will:
* Be people who had surgery for colon cancer between June 1, 2025 and May 31, 2026 at hospitals in Turkey that treat more than 30 colon cancer cases each year. * Have their medical and pathology data reviewed, including information about tumor location, biopsy results, surgery, and treatment.
This study will not involve any new treatments. Instead, it will use existing medical records to better understand how to improve care and identify people who may benefit from immunotherapy. Results from this study will be shared at scientific meetings and published in medical journals.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
Participants will be recruited from multiple high-volume general surgery centers across Turkey, including both public and private hospitals. The study will include institutions from major urban regions,as well as selected regional hospitals with established colorectal surgery programs.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
1,500 Participants
are grouped into 3 trial groupsGroup A: MLH1/PMS2 loss group
Group B: MSH2/MSH6 Loss Group
Group C: Sporadic Group (pMMR)
Trial outcomes
Primary outcomes
1
Prevalence and Anatomical Distribution of dMMR in Colon Cancer in Turkey
The proportion of colon cancer patients with mismatch repair deficiency (dMMR), stratified by tumor location (right-sided vs left-sided colon). This will be determined using immunohistochemical analysis of MMR protein expression (MLH1, PMS2, MSH2, MSH6) in resection specimens.
Time frame
Within 30 days post-operative based on final pathology reportSecondary outcomes
1
Frequency of MSI Reporting in Preoperative Endoscopic Biopsies
The percentage of colon cancer cases in which MSI status is documented in the preoperative endoscopic biopsy pathology report. The goal is to evaluate the current national practice of early MSI testing prior to definitive surgery.
Time frame
At time of initial diagnostic biopsy (baseline)2
Three-Year Disease-Free Survival (DFS) and Overall Survival Across MMR Subtypes
Comparison of 3-year disease-free survival (DFS) among patients with MLH1/PMS2 loss, MSH2/MSH6 loss, and pMMR (sporadic) tumors. DFS is defined as the time from surgery to the first recurrence, metastasis, or death from any cause.
Time frame
3 years from date of surgerySponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: